Dr Ian Tomlinson
Apollo Therapeutics Chairman
Ian Tomlinson has over 25 years of experience in the lifesciences sector from academic research to biotech startup to big pharma. He founded Domantis Limited with Sir Gregory Winter, which was acquired by GSK for $454 million. He then served as Senior VP, Head of Worldwide Business Development and Head of Biopharm R&D at GSK.
Following his departure from GSK, Ian is now Chairman of the Board at the Stevenage Bioscience Catalyst, UK’s first open innovation biomedical campus as well as Chairman of the Investment Committee for Apollo Therapeutics
Dr Tomlinson graduated from Trinity College, Cambridge, UK. He then spent 11 years at the MRC Laboratory of Molecular Biology, where he worked on antibody genes, antibody structure and various antibody technologies prior to starting his career in industry.